ClinVar Miner

Submissions for variant NM_001130987.2(DYSF):c.3886C>T (p.Gln1296Ter)

gnomAD frequency: 0.00003  dbSNP: rs727503911
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Eurofins Ntd Llc (ga) RCV000323235 SCV000331597 pathogenic not provided 2017-04-14 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV000809801 SCV000949977 pathogenic Qualitative or quantitative defects of dysferlin 2024-01-22 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Gln1278*) in the DYSF gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DYSF are known to be pathogenic (PMID: 17698709, 20301480). This variant is present in population databases (rs727503911, gnomAD 0.008%). This premature translational stop signal has been observed in individual(s) with distal myopathy (PMID: 16010686, 17698709, 25135358). ClinVar contains an entry for this variant (Variation ID: 167025). For these reasons, this variant has been classified as Pathogenic.
Johns Hopkins Genomics, Johns Hopkins University RCV000984259 SCV001430649 pathogenic Autosomal recessive limb-girdle muscular dystrophy type 2B 2020-06-16 criteria provided, single submitter clinical testing This DYSF variant (rs727503911) is rare (<0.1%) in a large population dataset4 (gnomAD: 4/279112 total alleles; 0.0014%; no homozygotes) and has an entry in ClinVar. This variant has been reported previously in a homozygous or compound heterozygous state in individuals affected with LGMDR2 or MMD1. This nonsense variant results in a premature stop codon in exon 34 of 56 likely leading to nonsense?mediated decay and lack of protein production. We consider this variant to be pathogenic.
Revvity Omics, Revvity RCV000323235 SCV002021862 pathogenic not provided 2021-05-05 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV002492572 SCV002781083 pathogenic Miyoshi muscular dystrophy 1; Autosomal recessive limb-girdle muscular dystrophy type 2B; Distal myopathy with anterior tibial onset 2021-07-15 criteria provided, single submitter clinical testing
CeGaT Center for Human Genetics Tuebingen RCV000323235 SCV004154967 pathogenic not provided 2023-04-01 criteria provided, single submitter clinical testing DYSF: PVS1, PM2, PM3
Baylor Genetics RCV003467211 SCV004194175 pathogenic Miyoshi muscular dystrophy 1 2024-03-13 criteria provided, single submitter clinical testing
Neuberg Centre For Genomic Medicine, NCGM RCV000984259 SCV005373711 uncertain significance Autosomal recessive limb-girdle muscular dystrophy type 2B 2023-05-20 criteria provided, single submitter clinical testing The observed stop gained c.3886C>T(p.Gln1296Ter) variant in DYSF gene has been reported previously in homozygous or compound heterozygous state in individual(s) affected with limb-girdle muscular dystrophies (LGMD2) (Stehlíková et al., 2014; Rufibach et al., 2023). This variant is reported with the allele frequency of 0.001% in the gnomAD Exomes. This variant has been reported to the ClinVar database as Pathogenic (multiple submitters). This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DYSF are known to be pathogenic (Nguyen et al., 2007). Computational evidence (MutationTaster - Disease causing automatic) predicts damaging effect on protein structure and function for this variant. For these reasons, this variant has been classified as Pathogenic.
Counsyl RCV000984259 SCV001132383 pathogenic Autosomal recessive limb-girdle muscular dystrophy type 2B 2016-11-18 no assertion criteria provided clinical testing
Natera, Inc. RCV000984259 SCV001462798 pathogenic Autosomal recessive limb-girdle muscular dystrophy type 2B 2020-09-16 no assertion criteria provided clinical testing
PreventionGenetics, part of Exact Sciences RCV003917498 SCV004736704 pathogenic DYSF-related disorder 2023-11-14 no assertion criteria provided clinical testing The DYSF c.3832C>T variant is predicted to result in premature protein termination (p.Gln1278*). This variant was reported in individuals with DYSF-related muscular dystrophy (Nguyen et al 2005. PubMed ID: 16010686; Klinge et al 2009. PubMed ID: 19528035; Moore et al 2021. PubMed ID: 33610434; Stehlíková et al 2014. PubMed ID: 25135358). This variant is reported in 0.0080% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/2-71827961-C-T). Nonsense variants in DYSF are expected to be pathogenic. This variant is interpreted as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.